InvaplexAR-Detox is an injectable Shigella vaccine that uses a novel combination of conserved invasion plasmid antigen (Ipa) proteins (IpaB and IpaC) with a serotype-specific bacterial attenuated LPS . Based on testing in animal models of shigellosis, immunisation with the vaccine not only prevents bloody diarrhea but also the intestinal inflammation associated with Shigella infection that is an important risk factor for the development of stunting among infants and children in LMICs. InvaplexAR-Detox has been tested in a phase I trial in adults in the USA where it demonstrated excellent safety and immunogenicity.